Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201203, China.
Atherosclerosis. 2012 Sep;224(1):43-50. doi: 10.1016/j.atherosclerosis.2012.06.066. Epub 2012 Jul 7.
To investigate SCM-198 (also known as "leonurine"), a compound in Herba leonuri, as well as its effect on the progression of atherosclerosis in hypercholesterolemic rabbits and underlying mechanisms.
Thirty New Zealand male White rabbits (5 groups, n = 6) were fed either a normal diet or a high-cholesterol diet (1%). The rabbits on the high-cholesterol diet received treatments of low, moderate, and high doses of SCM-198 and placebo concurrently. Eight weeks later, the animals underwent ultrasonographic imaging. They were then sacrificed for further pathological and molecular biological analysis.
SCM-198-treated rabbits showed a significant alleviation in the development of atherosclerosis in a dose-dependent manner. The lesions were smaller after the SCM-198 treatments. In addition, the elasticity of the arteries and hemodynamic status improved, accompanied with a decrease in smooth muscle cell migration and, macrophage infiltration, as well as the expression of platelet-endothelial cell adhesion molecule-1 (PECAM-1) in the aortas. Marginal changes in the lipid parameters were found in the SCM-198-treated rabbits, with high-density lipid cholesterol (HDL-C) elevation and triglyceride (TG) reduction at the high dose. SCM-198 treatment dose-dependently reduced levels of serum soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), as well as the mRNA levels of VCAM-1, IL-6, TNF-α, monocyte chemoattractant protein-1 (MCP-1), iNOS and MMP-9 in the aorta. In addition, SCM-198 also dose-dependently increased the total antioxidant capacities and in parallel decreased the lipid peroxidation levels in the serum and liver. The antioxidant effects of SCM-198 were implicated by the enhanced activities of catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx) and levels of glutathione (GSH) in the liver, as well as the mRNA levels of CAT, SOD-1 and GPx in the aorta.
In a rabbit atherosclerotic model, SCM-198 dose-dependently ameliorated the progression of atherosclerotic lesions and vascular dysfunction accompanied by the suppression of inflammatory factors and oxidative stress. These findings suggested that SCM-198 might be a potential agent for the treatment of atherosclerosis.
研究益母草中的化合物 SCM-198(也称为“益母草碱”)对高脂血症兔动脉粥样硬化进展的影响及其作用机制。
30 只新西兰雄性白兔(5 组,每组 6 只)分别给予正常饮食或高胆固醇饮食(1%)。给予高胆固醇饮食的兔子同时给予 SCM-198 低、中、高剂量和安慰剂治疗。8 周后,进行超声成像。然后处死动物进行进一步的病理和分子生物学分析。
SCM-198 治疗组兔动脉粥样硬化的发展呈剂量依赖性显著缓解。SCM-198 治疗后病变较小。此外,动脉弹性和血液动力学状态得到改善,同时伴有平滑肌细胞迁移减少、巨噬细胞浸润减少,以及主动脉血小板内皮细胞黏附分子-1(PECAM-1)表达减少。SCM-198 治疗组血脂参数有轻微变化,高密度脂蛋白胆固醇(HDL-C)升高,甘油三酯(TG)降低。SCM-198 治疗剂量依赖性降低血清可溶性血管细胞黏附分子-1(sVCAM-1)、可溶性细胞间黏附分子-1(sICAM-1)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)水平,以及主动脉 VCAM-1、IL-6、TNF-α、单核细胞趋化蛋白-1(MCP-1)、诱导型一氧化氮合酶(iNOS)和基质金属蛋白酶-9(MMP-9)mRNA 水平。此外,SCM-198 还剂量依赖性地增加了血清和肝脏中的总抗氧化能力,同时降低了脂质过氧化水平。SCM-198 通过增强肝脏中的过氧化氢酶(CAT)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GPx)活性和肝脏中谷胱甘肽(GSH)水平,以及主动脉中 CAT、SOD-1 和 GPx 的 mRNA 水平,发挥抗氧化作用。
在兔动脉粥样硬化模型中,SCM-198 呈剂量依赖性地改善动脉粥样硬化病变和血管功能障碍,同时抑制炎症因子和氧化应激。这些发现表明 SCM-198 可能是治疗动脉粥样硬化的潜在药物。